Jump to ContentJump to Main Navigation
Show Summary Details
More options …

The International Journal of Biostatistics

Ed. by Chambaz, Antoine / Hubbard, Alan E. / van der Laan, Mark J.

2 Issues per year


IMPACT FACTOR 2016: 0.500
5-year IMPACT FACTOR: 0.862

CiteScore 2016: 0.42

SCImago Journal Rank (SJR) 2016: 0.488
Source Normalized Impact per Paper (SNIP) 2016: 0.467

Mathematical Citation Quotient (MCQ) 2016: 0.09

Online
ISSN
1557-4679
See all formats and pricing
More options …

Commentary on "Principal Stratification -- a Goal or a Tool?" by Judea Pearl

Peter B. Gilbert / Michael G. Hudgens / Julian Wolfson
Published Online: 2011-09-20 | DOI: https://doi.org/10.2202/1557-4679.1341

This commentary takes up Pearl's welcome challenge to clearly articulate the scientific value of principal stratification estimands that we and colleagues have investigated, in the area of randomized placebo-controlled preventive vaccine efficacy trials, especially trials of HIV vaccines. After briefly arguing that certain principal stratification estimands for studying vaccine effects on post-infection outcomes are of genuine scientific interest, the bulk of our commentary argues that the “causal effect predictiveness” (CEP) principal stratification estimand for evaluating immune biomarkers as surrogate endpoints is not of ultimate scientific interest, because it evaluates surrogacy restricted to the setting of a particular vaccine efficacy trial, but is nevertheless useful for guiding the selection of primary immune biomarker endpoints in Phase I/II vaccine trials and for facilitating assessment of transportability/bridging surrogacy.

Keywords: principal stratification; causal inference; vaccine trial

About the article

Published Online: 2011-09-20


Citation Information: The International Journal of Biostatistics, ISSN (Online) 1557-4679, DOI: https://doi.org/10.2202/1557-4679.1341.

Export Citation

©2012 Walter de Gruyter GmbH & Co. KG, Berlin/Boston. Copyright Clearance Center

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[2]
Yiting Wang, Jesse A Berlin, José Pinheiro, and Marsha A Wilcox
Clinical Trials, 2015, Volume 12, Number 3, Page 265
[3]
Hannah Ensor, Robert J. Lee, Cathie Sudlow, and Christopher J. Weir
Journal of Biopharmaceutical Statistics, 2016, Volume 26, Number 5, Page 859
[4]
Peter B. Gilbert, Erin E. Gabriel, Xiaopeng Miao, Xiaoming Li, Shu-Chih Su, Janie Parrino, and Ivan S. F. Chan
Journal of Infectious Diseases, 2014, Volume 210, Number 10, Page 1573
[5]
Barton F. Haynes, Peter B. Gilbert, M. Juliana McElrath, Susan Zolla-Pazner, Georgia D. Tomaras, S. Munir Alam, David T. Evans, David C. Montefiori, Chitraporn Karnasuta, Ruengpueng Sutthent, Hua-Xin Liao, Anthony L. DeVico, George K. Lewis, Constance Williams, Abraham Pinter, Youyi Fong, Holly Janes, Allan DeCamp, Yunda Huang, Mangala Rao, Erik Billings, Nicos Karasavvas, Merlin L. Robb, Viseth Ngauy, Mark S. de Souza, Robert Paris, Guido Ferrari, Robert T. Bailer, Kelly A. Soderberg, Charla Andrews, Phillip W. Berman, Nicole Frahm, Stephen C. De Rosa, Michael D. Alpert, Nicole L. Yates, Xiaoying Shen, Richard A. Koup, Punnee Pitisuttithum, Jaranit Kaewkungwal, Sorachai Nitayaphan, Supachai Rerks-Ngarm, Nelson L. Michael, and Jerome H. Kim
New England Journal of Medicine, 2012, Volume 366, Number 14, Page 1275
[6]
Ying Huang, Peter B. Gilbert, and Julian Wolfson
Biometrics, 2013, Volume 69, Number 2, Page 301

Comments (0)

Please log in or register to comment.
Log in